From the Department of Neurosciences (D.P.S., D.S.S., D.G.C., J.M.H., K.M.L., J.V.F., L.A.H., D.G.), Psychiatry (J.V.F.), and Pathology (A.H., L.A.H.), University of California, San Diego.
Neurology. 2022 Nov 1;99(18):e2034-e2043. doi: 10.1212/WNL.0000000000201068. Epub 2022 Aug 26.
Patients with dementia with Lewy bodies perform worse than those with Alzheimer disease (AD) on tests of visual perception, but the clinical utility of these tests remains unknown because studies often had clinically diagnosed groups that may inadvertently cross-contaminate Lewy body disease (LBD) with pure AD pathology, used experimental tests not easily adaptable for clinical use, and had no way to examine relationships between the severity of LBD pathology and degree of cognitive impairment. Therefore, we sought to determine whether performance on a widely used clinical test of visuoperceptual ability effectively differentiates between patients with autopsy-confirmed LBD or AD and correlates with the severity of LBD pathology.
Patients with mild to moderate dementia (n = 42) and cognitively healthy controls (n = 22) performed a Fragmented Letters Test in which they identified letters of the alphabet that were randomly visually degraded by 70% and additional visuospatial and episodic memory tests. At autopsy, dementia cases were confirmed to have LBD (n = 19), all with concomitant AD, or only AD (n = 23). Severity of α-synuclein pathology in the hippocampus and neocortex was rated on an ordinal scale.
Patients with LBD performed worse than those with AD (B = -2.80 ± 0.91, = 0.009) and healthy controls (B = -3.34 ± 1.09, = 0.01) on the Fragmented Letters Test after adjustment for age, sex, education, Mini-Mental State Examination score, and ability to name intact letters. Patients with AD did not differ from controls (B = -0.55 ± 1.08, = 0.87). The test effectively distinguished between patients with LBD or AD with 73% sensitivity and 87% specificity, and the area under the curve in receiver operating characteristic analyses was 0.85 (95% CI 0.72-0.95), higher than for standard tests of visuospatial ability (Block Design; 0.72; CI 0.35-0.75) or memory (California Verbal Learning Test, trials 1-5; 0.55; CI 0.57-0.88). Fragmented Letters Test scores were negatively correlated with LBD pathology density ratings in hippocampus and neocortical regions (Spearman r = -0.53 to -0.69).
Fragmented Letters Test performance can effectively differentiate patients with LBD pathology from those with only AD pathology at a mild to moderate stage of dementia, even when LBD occurs with significant concomitant AD pathology, and may also be useful for gauging the severity of cortical α-synuclein pathology in those with LBD.
与阿尔茨海默病(AD)患者相比,路易体痴呆(LBD)患者在视觉感知测试中的表现更差,但这些测试的临床应用价值尚不清楚,因为研究中经常使用临床诊断的组别,这些组别可能会无意中将 LBD 与单纯 AD 病理学交叉污染,使用实验性测试,这些测试不易适用于临床使用,并且无法检查 LBD 病理学严重程度与认知障碍程度之间的关系。因此,我们试图确定广泛使用的视觉感知能力临床测试的表现是否可以有效区分经尸检证实的 LBD 或 AD 患者,以及是否与 LBD 病理学的严重程度相关。
轻度至中度痴呆(n = 42)的患者和认知健康对照者(n = 22)进行了一项片段字母测试,在此测试中,他们识别了字母表中随机以 70%的比例进行视觉降级的字母,以及额外的视觉空间和情节记忆测试。在尸检时,痴呆病例被证实患有 LBD(n = 19),均伴有 AD,或仅患有 AD(n = 23)。海马体和新皮层中α-突触核蛋白病理学的严重程度按等级量表评定。
调整年龄、性别、教育程度、简易精神状态检查评分和完整字母命名能力后,LBD 患者在片段字母测试中的表现比 AD 患者(B =-2.80 ± 0.91, = 0.009)和健康对照组(B =-3.34 ± 1.09, = 0.01)差。AD 患者与对照组无差异(B =-0.55 ± 1.08, = 0.87)。该测试有效地区分了 LBD 或 AD 患者,其敏感性为 73%,特异性为 87%,接受者操作特征曲线下的面积为 0.85(95%CI 0.72-0.95),高于标准的视觉空间能力测试(方块设计;0.72;CI 0.35-0.75)或记忆测试(加利福尼亚语言学习测验,第 1-5 项试验;0.55;CI 0.57-0.88)。片段字母测试分数与海马体和新皮层区域的 LBD 病理学密度评分呈负相关(Spearman r =-0.53 至-0.69)。
在轻度至中度痴呆的轻度至中度阶段,片段字母测试的表现可以有效地区分具有 LBD 病理学的患者与仅具有 AD 病理学的患者,即使当 LBD 与明显的 AD 病理学共存时,该测试也可能对评估 LBD 患者皮质α-突触核蛋白病理学的严重程度有用。